XBIT Key Statistics, Chart & Performance
The current stock price of XBIT is 2.4 USD. In the past month the price decreased by -9.43%. In the past year, price decreased by -65.47%.
XBIT Latest News, Press Relases and Analysis
XBIT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About XBIT
Company Profile
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 92 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products, including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Company Info
XBIOTECH INC
5217 Winnebago Lane
Austin TEXAS 78744 US
CEO: John Simard
Employees: 92
Phone: 15123862900
XBIOTECH INC / XBIT FAQ
Can you describe the business of XBIOTECH INC?
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 92 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products, including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
What is the current price of XBIT stock?
The current stock price of XBIT is 2.4 USD. The price decreased by -5.88% in the last trading session.
Does XBIOTECH INC pay dividends?
XBIT does not pay a dividend.
How is the ChartMill rating for XBIOTECH INC?
XBIT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of XBIOTECH INC (XBIT)?
XBIOTECH INC (XBIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.98).
What is XBIOTECH INC worth?
XBIOTECH INC (XBIT) has a market capitalization of 73.18M USD. This makes XBIT a Micro Cap stock.
XBIT Technical Analysis
XBIT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XBIT. While XBIT has a great health rating, there are worries on its profitability.
XBIT Financial Highlights
Over the last trailing twelve months XBIT reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS increased by 8.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.31% | ||
| ROE | -17.83% | ||
| Debt/Equity | 0 |